Accessibility StatementSkip Navigation RADNOR, Pa., Oct. 29, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its third fiscal quarter ended September 30, 2025. "Avantor's diverse portfolio, strong production capabilities, and long-standing customer relationships provide a strong foundation for sustained value creation," said Emmanuel ...

Avantor Inc. (NYSE:AVTR) is one of the best large cap stocks to buy under $20. On October 15, Avantor announced a partnership with BlueWhale Bio, which is a commercial-stage company that transforms immune cell therapy manufacturing. The collaboration addresses the unmet needs in CAR-T production by streamlining manufacturing, reducing variability, and shortening the time it takes to get therapies to patients. The core of the partnership combines Avantor’s expertise in bioprocessing and custom ancillary-re ...

Core Insights - Avantor, Inc. has announced a collaboration with p-Chip Corporation to develop a new generation of "Smart Consumables" that integrate microtransponder technology for enhanced traceability and digital process control in pharmaceutical and clinical workflows [1][2][3] Group 1: Collaboration Details - The partnership aims to leverage Avantor's expertise and scale alongside p-Chip's digital microtransponder technology to meet the needs of strategic customers in life sciences, diagnostics, bio-manufacturing, and healthcare [2][3] - Smart Consumables will include laboratory items such as vials, slides, cassettes, tubes, and plates, each embedded with a durable p-Chip microtransponder that provides a unique identifier for secure tracking [3][4] Group 2: Market Demand and Applications - There is a growing demand for precision and individualized therapies, which necessitates high-fidelity sample traceability and secure Chain-of-Identity (COI) compliance [4] - Personalized therapeutics, including advanced cell and gene therapies, require secure identification and monitoring of patient samples throughout their therapeutic journey [4] Group 3: Strategic Importance - The innovation aligns with Avantor's mission to enable scientific breakthroughs and meet high-value customer needs in personalized medicine [5] - The collaboration is expected to enhance traceability and compliance in laboratory workflows, streamlining quality control and accelerating digital transformation in pharmaceutical and healthcare processes [5]

Core Insights - Avantor (AVTR) has entered a strategic partnership with BlueWhale Bio to enhance CAR-T cell therapy manufacturing, combining Avantor's bioprocessing expertise with BlueWhale's Synecta cell-derived nanoparticle technology [1][8] - The collaboration aims to improve scalability, reduce variability, and shorten time-to-patient in CAR-T production, thereby expanding patient access and strengthening Avantor's position in the cell therapy market [2][10] Company Summary - The partnership is expected to deepen Avantor's role in the cell therapy manufacturing landscape by leveraging its bioprocessing capabilities to scale BlueWhale's CDNP platform, which has shown promising results in preclinical and clinical programs [9] - Avantor's market capitalization currently stands at $9.46 billion [6] - Following the announcement, Avantor's shares remained flat, with a year-to-date decline of 30.8%, contrasting with the industry's 0.5% growth and the S&P 500's 14.5% gain [3] Industry Summary - The global cell and gene therapy manufacturing market was valued at $7.28 billion in 2022 and is projected to grow at a CAGR of 26.6% from 2023 to 2030, indicating favorable industry prospects for companies like Avantor [11]

Core Insights - Avantor, Inc. has announced a strategic partnership with BlueWhale Bio to enhance CAR-T cell therapy manufacturing, addressing key challenges in the production process [1][2][3] Company Overview - Avantor is a leading global provider of mission-critical products and services for the life sciences and advanced technologies industries, supporting over 300,000 customer locations in 180 countries [4] - BlueWhale Bio focuses on transforming immune cell therapy manufacturing, aiming to accelerate the growth and adoption of cell-based therapies [5] Partnership Details - The collaboration combines Avantor's bioprocessing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle (CDNP) platform, which aims to streamline CAR-T production by reducing variability and shortening time-to-patient [2][3] - The partnership will produce GMP-grade CDNP materials to support next-generation manufacturing approaches, potentially expanding patient access and manufacturing capacity in the cell therapy sector [2][3] Technological Innovations - BlueWhale Bio's Synecta™ platform has shown promising results in preclinical and clinical programs, demonstrating earlier cell division, higher cell yields, and fewer process interventions, which could lead to reduced CAR-T process time and lower cell stress during manufacturing [3] - The first product from BlueWhale Bio, Synecta™ T1, is currently being used in a phase 1 clinical trial for a 3-day CAR-T manufacturing process [5]

Core Points - Gregory L. Summe will become the next Chairman of the Board for Avantor, Inc. starting January 1, 2026, succeeding Jonathan Peacock who will step down at the end of 2025 after nearly nine years of service [1] - Summe has been an independent director since 2020 and has served as Chairman of the Nominating and Governance Committee, as well as a member of the Compensation Committee [2] - Peacock expressed confidence in the new leadership under Summe and CEO Emmanuel Ligner, highlighting the Board's diverse expertise in life sciences [3] Company Overview - Avantor, Inc. is a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, supporting over 300,000 customer locations in 180 countries [4]

Core Insights - Avantor, Inc. has appointed Gregory T. Lucier to its Board of Directors, bringing over 30 years of leadership experience in the life sciences industry [1][3] - Lucier is the founder and current Executive Chairman and CEO of Corza Medical, and has held significant leadership roles in other healthcare companies, including NuVasive and Life Technologies [2][4] - The appointment is expected to enhance Avantor's focus on growth and profitability in its Lab Solutions and Bioscience Production segments [3] Company Overview - Avantor is a global provider of mission-critical products and services to the life sciences and advanced technology industries, serving over 300,000 customer locations in 180 countries [6] - The company aims to enable breakthroughs in medicine, healthcare, and technology through its comprehensive portfolio [6] Leadership Background - Gregory T. Lucier has a proven track record of driving growth and innovation in the healthcare sector, having previously led Life Technologies to over $4 billion in sales before its acquisition by Thermo Fisher Scientific in 2014 [4] - Lucier holds a bachelor's degree in industrial engineering from Pennsylvania State University and an MBA from Harvard Business School [5]

Core Insights - Avantor Inc. (NYSE:AVTR) experienced a share price increase of 5.41% to close at $12.48, driven by investor interest in pharmaceutical stocks ahead of new tariffs on imported drugs [1][3]. Group 1: Company Performance - Avantor Inc. is positioned to benefit from the 100% tariff on imported branded or patented pharmaceutical products, which is set to begin on October 1 [2][3]. - The imposition of tariffs is expected to raise the prices of imported pharmaceutical brands, making domestic alternatives like Avantor's more attractive to customers [3]. Group 2: Industry Context - The U.S. government is conducting a national security investigation to determine the implications of tariffs on pharmaceuticals, indicating a broader regulatory focus on the industry [3]. - The tariffs are part of a strategy to encourage domestic manufacturing in the pharmaceutical sector, which may lead to increased competitiveness for U.S.-based companies like Avantor [2][3].

Core Points - Avantor, Inc. will release its third quarter 2025 financial results on October 29, 2025, before the market opens [1] - A conference call to discuss the results will be held on the same day at 8:00 a.m. Eastern Time [1][2] - Avantor is a leading global provider of mission-critical products and services in the life sciences and advanced technology industries, serving over 300,000 customer locations in 180 countries [3]

Group 1: Company Performance - Broyhill Asset Management reported a 3.7% net appreciation in its Broyhill Partners fund for Q2 2025, which is lower than the MSCI All Country World Index's return of 11.7% for the same period [1] - Avantor, Inc. (NYSE:AVTR) experienced a 17% decline in its stock price during Q2 2025, continuing its downward trend into Q3 after missing earnings and cutting guidance [3] - Avantor, Inc. reported flat revenue of $1.68 billion year-over-year on an organic basis for Q2 2025 [4] Group 2: Market Context and Competitors - The competitive environment in the biopharma and healthcare sectors has intensified due to budget cuts in academic research and commercial pharmaceuticals, leading to market share losses for Avantor [3] - Following the decline in Avantor's stock, Broyhill Asset Management shifted some exposure to competitor Thermo Fisher Scientific while evaluating market dynamics [3] Group 3: Investor Sentiment and Future Outlook - An activist investor has acquired a significant stake in Avantor and is pushing for a board overhaul or strategic review, indicating potential changes in governance [3] - Despite recent challenges, Broyhill Asset Management believes Avantor represents significant value at current levels and anticipates a positive shift with new board perspectives [3] - The number of hedge funds holding Avantor increased from 38 to 49 in Q2 2025, suggesting growing interest among institutional investors [4]